Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07274787 · ClinicalTrials.gov registry record · NA
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
A NA study, sponsored by University of Cincinnati.
- Not yet
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT07274787 is a NA study that has not yet begun recruiting, run by University of Cincinnati. The registered enrollment target is 10 participants.
The verdict
NCT07274787, a NA study, has not yet begun recruiting, sponsored by University of Cincinnati.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will evaluate the safety and early effectiveness of the NaviFUS system with concomitant microbubble administration in conjunction with BEV in recurrent GBM patients.
Interventions
- DRUG Bevacizumab
- DRUG Lumason
- DEVICE NaviFUS System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-12-01 |
| Est. Completion | 2029-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07274787
The ClinicalTrials.gov registry entry for NCT07274787 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT07274787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07274787 about?
NCT07274787 is a clinical study titled "Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma". This study will evaluate the safety and early effectiveness of the NaviFUS system with concomitant microbubble administration in conjunction with BEV in recurrent GBM patients.
What is the current status of trial NCT07274787?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2026-12-01. Estimated completion is 2029-12-01.
What interventions are being tested in trial NCT07274787?
The interventions under investigation include: Bevacizumab (DRUG), Lumason (DRUG), NaviFUS System (DEVICE).
Who is sponsoring clinical trial NCT07274787?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.